Find a Trial

Trial Summary

Protocol No.RAON-IIR-IUSCC-0710
Principal InvestigatorShiue, Kevin
Age GroupAdult
TitleRadiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
DescriptionTo evaluate objective response rates of brain metastasis after ICI concurrent with SRS at six months with regard to symptomatic radiation necrosis, defined as an actuarial 6-month rate of clinical symptomatology requiring steroid administration (i.e. Decadron), bevacizumab (Avastin), and/or operative intervention concomitant with advanced and routine brain imaging findings consistent with radiation necrosis.
Key EligibilityIn order to be eligible to take part in this trial, patients must have:
  • Brain MRI-confirmed 1-10 solid tumor brain metastases
  • Biopsy-confirmed primary malignancy
For a full list of participation criteria, please visit
Applicable Disease SitesBrain and Nervous System
Participating InstitutionsIndiana University (IU)
    Oregon Health & Science University
      Treatment TypeTreatment
      ContactPhone: (317) 278-5632